Aeolus Pharmaceuticals (OTC: AOLS) is developing compounds with demonstrated anti-fibrotic, anti-inflammatory, anti-infective and neuro-protective properties. The company’s first compound, AEOL 10150, is being developed with funding from the U.S. Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, as well as a treatment for pulmonary fibrosis. Aeolus’ strategy is to leverage the substantial investment in toxicology, manufacturing and preclinical and clinical studies of AEOL 10150 made by U.S. government agencies, including the contract with BARDA, to efficiently develop the compound for use in idiopathic pulmonary fibrosis and oncology. For more information, visit the company’s website at www.aolsrx.com.